MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

NCT06671938 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-03-10

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.

Conditions

Interventions

DRUG

exidavnemab

The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)

DRUG

Placebo Comparator

The trial medication will be administered as an intravenous (IV) infusion

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • BioArctic AB

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2026-08-17
Completion
2026-08-17
FDA Drug
Yes

Countries

  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671938 on ClinicalTrials.gov